Cipramil (Citalopram)

Quick links

Choose a section

Quick links to important sections

Advertisements

Cipramil (Citalopram)

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Cipramil (Citalopram)

Cipramil (Citalopram) is a foundational psychotropic medication defined by its targeted action within the central nervous system. This section strictly defines the medicine’s identity, composition, and general purpose.

Property Description
Active ingredient Citalopram (as Hydrobromide salt)
Form Oral tablet, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Supporting emotional stability and mood regulation
Origin Synthetic compound
Prescription Status Prescription-only (-only)

What Type of Medicine is Cipramil (Citalopram)?

Cipramil is a synthetic compound that is clinically recognized for supporting emotional health, which aligns with its classification as an antidepressant and a psychotropic medication. Its core active ingredient is Citalopram, which belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) pharmacological class. This classification is supported by pharmacological studies demonstrating its high degree of selectivity toward inhibiting serotonin reuptake compared to its effects on other neurotransmitters, distinguishing it among newer classes of antidepressants. This targeted action is clinically supported in adults with mood disorders.

Composition, Forms, and General Therapeutic Purpose

The medicine is defined as a single-active ingredient product where Citalopram hydrobromide is the key chemical substance, recognized as a bicyclic phthalane derivative. It is available for oral administration in two principal dosage form(s): the oral tablet and the oral solution. A crucial characteristic is that Citalopram is a racemic mixture, meaning it is chemically composed of both active and less active mirror-image forms. The compound's function is to inhibit the reuptake of the monoamine neurotransmitter serotonin, thereby increasing its functional availability in the central nervous system. This sustained serotonin signaling supports the brain's ability to regulate mood and emotional resilience, which is the general benefit sought by patients.

Regulatory References

  1. NIH Drug Summary
Advertisements

What side effects are possible with Cipramil (Citalopram)?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Cipramil (Citalopram) based on the frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions, classified as Very Common (ge 1/10) in official labeling, include Headache, Dry mouth, Nausea, Increased sweating, Somnolence (Drowsiness), and Insomnia. Reactions categorized as Common (ge 1/100 to < 1/10) encompass Dizziness, Tremor, Agitation, Anxiety, Vomiting, Diarrhoea, Constipation, and various forms of Sexual dysfunction. These effects are generally grouped into System-Organ Classes such as Nervous system disorders, Gastrointestinal disorders, and Psychiatric disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory warnings highlight the risk of serious adverse reactions, which are generally rare. These include QT-interval prolongation and a serious arrhythmia known as Torsade de Pointes, requiring caution in patients with pre-existing heart conditions or those using other QT-prolonging medicines. The label also documents the risk of Serotonin Syndrome, particularly when Citalopram is combined with other serotonergic agents, and Hyponatraemia (low sodium levels), especially in older adults.

Safety Restrictions: Citalopram is strictly contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). Additionally, official labeling specifies that use is contraindicated in patients with known congenital long QT syndrome or severe hepatic impairment.


Exposure-Related Patterns

Some adverse effects, such as Anxiety and Agitation, are officially documented to be potentially more likely to occur at the start of treatment or following dose adjustments. Furthermore, specific discontinuation symptoms are documented to occur upon cessation or reduction of therapy.

Advertisements

Overdose and Emergency Response

Citalopram overdosage is defined by potential toxic effects spanning multiple physiological systems, primarily the cardiovascular and central nervous systems. Documented, non-severe manifestations may include drowsiness, somnolence, dizziness, tremor, vomiting, and sinus tachycardia. However, the official profile emphasizes the risk of severe, life-threatening outcomes.

The most critical documented risks involve cardiovascular toxicity, including dose-dependent QT-Prolongation, which can progress to malignant arrhythmias such as Torsade de Pointes (TdP), ventricular tachycardia, and sudden death. Severe neurological manifestations include the occurrence of seizures and the potential development of Serotonin Syndrome, which may present with autonomic instability, hyperthermia, and coma.

Immediate medical attention must be sought if any signs of severe cardiac effects, such as irregular heartbeat, shortness of breath, dizziness, or fainting, are experienced. Regulators advise contacting a Poison Center for management guidance. Overdose management is strictly symptomatic and supportive, as no specific antidote is known. Hospital monitoring requirements include continuous ECG monitoring and correction of electrolyte imbalances (e.g., hypokalemia, hypomagnesemia). Patients who are elderly or have hepatic impairment are noted in official documents to be at increased risk of toxicity.

Advertisements

Therapeutic Uses of Cipramil (Citalopram)

Cipramil (Citalopram) is applied in clinical settings that involve acute or unstable symptom patterns, focusing on therapeutic support for symptom management across several key domains. It is commonly used across conditions presenting with acute episodes, such as Major Depressive Disorder (MDD), but also Panic Disorder and sometimes Generalized Anxiety Disorder and Obsessive-Compulsive Disorder. This medication assists with maintaining functional stability and helps to improve mood and reduce anxiety.

The medicine is relevant for easing symptom clusters that may become intense or disruptive, such as persistent sadness, feelings of hopelessness, anhedonia (loss of pleasure), and the sudden onset of panic attacks. It is often used during phases when symptoms become more noticeable, offering supportive relief that may assist with managing difficult episodes. The support provided may assist with easing distress and contributes to supporting day-to-day comfort.

Quick Fact: Relief for Functional Strain
This medication is applied in addressing symptoms that interfere with daily functioning, including disruptive changes to sleep patterns, persistent low energy, and difficulty with concentration. It supports the moderation of these neurovegetative and cognitive difficulties.

The overall benefit is considered relevant for supporting emotional stability and assists with maintaining capacity for functional stability when symptoms intensify.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Cipramil (Citalopram) eligibility is strictly defined by regulatory authorities based on absolute prohibitions and specific population restrictions. The established standard population for use is adults who possess no specified contraindications.

Absolute Contraindications

Use of Citalopram is contraindicated and must not occur in patients taking Monoamine Oxidase Inhibitors (MAOIs) or the medicine Pimozide, due to the risk of severe reactions. The medicine is also prohibited for individuals with a history of QT interval prolongation or those using any other medication known to prolong the QTc interval. Patients with a known Hypersensitivity to Citalopram or its components are ineligible.

Age and Conditional Restrictions

Citalopram is not approved for use in children and adolescents under 18 years of age. For older adults (over 60), the label requires a restricted maximum dose. This dose limitation also applies to patients with reduced liver function (hepatic impairment). Use during pregnancy and while breastfeeding is generally not recommended. Use is considered conditional in populations with a history of seizures or Bipolar Disorder.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Cipramil (Citalopram) is structured around high-risk drug combinations and pharmacokinetic pathway management.

Contraindicated Combinations

Co-administration with all Monoamine Oxidase Inhibitors (MAOIs), including Linezolid, is strictly prohibited due to the risk of Serotonin Syndrome. A mandatory 14-day separation period is required when switching between Citalopram and an MAOI. Co-administration with agents known to prolong the QT-interval, such as Pimozide and certain antiarrhythmics, is also prohibited by regulatory authorities.

Pharmacokinetic and Pharmacodynamic Interactions

A key Pharmacokinetic Interaction involves the inhibition of the CYP2C19 enzyme by certain co-administered medicines (e.g., cimetidine). This interaction reduces Citalopram's clearance, resulting in documented increased plasma concentrations. This exposure modification triggers an interaction-related restriction on the maximum recommended dose in the elderly, patients with hepatic impairment, and known CYP2C19 poor metabolizers.

Further Pharmacodynamic Interactions exist with other serotonergic drugs (e.g., triptans, tramadol, lithium), which also increase the risk of Serotonin Syndrome. Co-administration with substances that interfere with hemostasis, such as NSAIDs or anticoagulants (e.g., warfarin), increases the official risk of abnormal bleeding. Alcohol and the herbal product St. John's Wort are not recommended.

Advertisements

Mechanism of Action

How Cipramil (Citalopram) Works

Citalopram primarily acts by influencing activity within the serotonergic system through two distinct mechanistic domains: immediate molecular action and delayed neuroadaptive change.


Selective Blockade of the Serotonin Transporter

Citalopram's core mechanism is the selective inhibition of the Serotonin Transporter (SERT), the protein responsible for clearing the neurotransmitter Serotonin (5-HT) from the synaptic cleft. By blocking the SERT, Citalopram rapidly and efficiently increases the concentration of 5-HT in the synaptic cleft, thereby potentiating signal transmission across the central neural pathways that regulate affective signaling.


Mechanism of Delayed Neuroadaptation

The full manifestation of the mechanism is not immediate but is dependent on time-lapsed neuroadaptive signaling. The sustained elevation of 5-HT levels triggers regulatory changes, including the desensitization of certain inhibitory autoreceptors, a process which requires several weeks to complete. This neuroadaptation establishes a sustained serotonergic tone, supporting the brain's internal mechanisms for regulating neural signaling in affective circuits.


Off-Target Modulation of Cardiac Ion Channels

At higher concentrations, the molecule engages a secondary, off-target mechanism by inhibiting hERG potassium channels in cardiac tissue. This channel antagonism results in a concentration-dependent delay in cardiac repolarization, which imposes limits on systemic exposure and thereby on the achievable degree of serotonergic potentiation.

Advertisements

Dosage and Administration Information

Cipramil is administered exclusively by the oral route, available as film-coated tablets and an oral solution. Administration occurs once daily, and the dose may be taken in the morning or evening, with or without food. The official dosing schedule for adults typically starts at 20 mg daily. The dose may be increased after a minimum of one week, with the maximum recommended dose for the general adult population set at 40 mg once daily.

Population-Specific Use Restrictions

The regulatory guidance establishes clear dose limitations for specific patient groups. For older adults (generally defined as 60 years and over) and patients with hepatic impairment, the maximum recommended daily dose is restricted to 20 mg. This 20 mg maximum also applies to known CYP2C19 poor metabolizers.

Course and Procedural Guidance

Treatment duration commonly extends for at least 6 months to establish stability. When discontinuing the medicine, the dose must be gradually reduced (tapered) over a period of at least one to two weeks to follow official procedural guidelines. If a dose is missed, the labeled instruction is to skip the missed dose and continue with the regular schedule, without doubling the next dose. The oral solution requires the use of a marked measuring device to ensure dosage accuracy.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Cipramil (Citalopram)

Evidence Overview for Major Depressive Disorder (MDD)

Citalopram was studied for conditions characterized by fluctuating or episodic manifestations, such as Major Depressive Disorder (MDD). The core evidence comes from short-term, placebo-controlled Randomized Controlled Trials (RCTs) that were studied for changes in depressive symptom severity. Researchers examined outcomes related to systemic or functional imbalance by using validated rating scales to monitor changes in depressive symptom severity in the observed populations.

The trials examined patterns related to treatment response and remission. Research describes group patterns observed in the studies when comparing the active group to the placebo group over the acute follow-up durations. However, data show patterns related to symptom remission rates; however, findings were mixed across different studies and analyses.

Research Structure for Panic Disorder

Citalopram was observed in studies examining temporary physiological imbalance, specifically for conditions associated with acute or disruptive episodes, such as Panic Disorder. The research primarily consists of short-term RCTs that included both placebo and sometimes active comparator groups. These trials explored outcomes describing episodic or acute changes, with the primary focus on monitoring the frequency of panic attacks in the study population.

Studies report how symptoms evolved in the observed populations for change in the frequency of these episodes over the acute observation period. Follow-up durations were limited, as these studies mainly focused on the acute management phase, typically lasting around 8 weeks. Therefore, there is limited information for long-term outcomes related to symptom recurrence following acute treatment.

Studies in Children, Adolescents, and Older Adults

Research has also examined Citalopram's use across different age cohorts. The study populations for MDD included dedicated trials focusing on children and adolescents, to explore short-term symptom changes in these specific groups. Separate analyses and studies also were evaluated in older adults (typically aged 60 and above) to monitor outcomes reflecting daily functioning or activity level in this population. Findings describe patterns observed in the studies in these subgroup analyses, but the results apply only to the populations studied.

Quality and Limitations of the Evidence

The overall body of evidence highlights what is known—and what is still uncertain—about Citalopram. Acknowledged research limitation frames include findings were mixed regarding certain primary endpoints, such as remission rates. Systematic reviews have documented concerns related to the quality of reporting in some of the original clinical trials. Evidence quality varies across studies, and the scientific literature indicates that data are still emerging in several areas, with certainty remains low for some specialized populations or specific long-term outcomes.

Key Studies & References

  1. NIH MedlinePlus Drug Information: Citalopram
  2. Citalopram: NIH NCBI Bookshelf Drug Summary
  3. Selective serotonin reuptake inhibitors for panic disorder and agoraphobia: a systematic review
  4. Antidepressant treatment in children and adolescents
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cipramil (Citalopram) (FAQ)


Q: How long does it usually take to feel the initial effects of Cipramil (Citalopram)?

Regulatory documents indicate that the initial effects related to mood and emotional support are generally described to become apparent within one to four weeks of starting treatment. Because the brain's adjustment to the medicine requires time, official information describes the onset of action as gradual.


Q: What is the expected timeline for the full benefits of Cipramil (Citalopram)?

The full effect is related to a delayed process of brain adjustment that requires time. Official documentation states that the full manifestation of therapeutic benefit may require several weeks of continued use. It is a process that unfolds over time rather than immediately.


Q: Do initial side effects of Cipramil (Citalopram), like nausea, generally go away?

Adverse effects, such as nausea, dry mouth, and increased sweating, are often reported in the beginning phase of treatment. While official documents list these common initial effects, they do not guarantee that every side effect will resolve or diminish over time.


Q: Can Cipramil (Citalopram) cause weight changes, like gain or loss?

Yes, official adverse reaction tables document the possibility of weight changes. Decreased appetite and weight decrease are listed as Common effects. Conversely, increased appetite and weight increase have also been noted as less common adverse reactions in regulatory sources.


Q: Are sexual side effects, such as reduced libido or difficulty with orgasm, common with Cipramil (Citalopram)?

Sexual dysfunction is officially documented as a Common adverse reaction associated with Citalopram use. This category includes effects such as reduced sex drive (libido), difficulties with ejaculation, and problems achieving orgasm, as noted in regulatory product information.


Q: Is there a risk of hyponatremia (low sodium levels in the blood) with Cipramil (Citalopram)?

The risk of Hyponatraemia (a documented medical condition involving low sodium levels in the blood) is noted in regulatory labeling. Official warnings suggest that this adverse reaction is more likely to occur when the medicine is used by older adults.


Q: What should be done if a dose of Cipramil (Citalopram) is missed?

Official directions for managing a missed dose state that the dose should be skipped entirely. The instruction is to resume the treatment by taking the next scheduled dose at the usual time. Regulatory guidance strictly advises against doubling the next dose.


Q: Can Citalopram tablets be crushed or split?

Citalopram is typically provided as a film-coated tablet, or as an oral solution. Regulatory guidelines for tablets usually require they are swallowed whole. Tablets should generally not be crushed or split unless the tablets are specifically scored and official information provides clear instructions allowing it for administration.


Q: Is Cipramil (Citalopram) the same as other SSRIs, like Escitalopram or Sertraline?

Cipramil is an SSRI, but it is chemically different from other medicines in the same class. Official chemical definitions state that Citalopram is a racemic mixture, meaning it contains both active and less active mirror-image forms of the molecule. Escitalopram, a related SSRI, is the pure active component (S-enantiomer) of Citalopram.


Q: Is Cipramil (Citalopram) considered addictive or habit-forming?

Official regulatory documentation does not classify Citalopram as a controlled substance (addictive drug). However, regulatory sources do detail the potential for discontinuation symptoms if the medicine is stopped abruptly, which is a physiological reaction different from drug addiction.


Q: How can taking Cipramil (Citalopram) affect a person's ability to drive or operate machinery?

Official labeling states that functions such as coordination, reaction time, and judgment may be affected. The official advice is to observe how the medicine affects the individual before operating dangerous machinery.


Q: What is the phenomenon of antidepressant poop-out or reduced effectiveness over time?

The clinical term 'poop-out' is not used in official regulatory documents. However, research evidence includes long-term continuation studies that examine relapse rates in patients, showing that therapeutic response may change over the course of treatment.


Q: Can taking Cipramil (Citalopram) cause a manic episode in people with an underlying condition?

The official label includes a warning about the potential for activation of mania or hypomania (a less severe form of mania). This effect has been reported in a small percentage of patients studied and is a known risk for individuals with or at risk for Bipolar Disorder.


Q: Is Cipramil (Citalopram) known to affect fertility or sperm quality?

Animal studies cited in regulatory documents suggest Citalopram may have an effect on sperm quality. While data in humans are less conclusive, the official label notes the potential for effects on reproductive health and fertility.


Q: Is there a known effect of Citalopram on appetite?

Yes, official adverse reaction tables document changes in appetite. Both decreased appetite (a Common effect) and increased appetite (an Uncommon effect) are listed in regulatory sources.


Q: Does Cipramil (Citalopram) have a known effect on blood pressure?

Adverse reaction lists in regulatory documents indicate that Citalopram may be associated with changes in blood pressure. Both Hypotension (low blood pressure) and Hypertension (high blood pressure) are documented as Common effects.


Q: Is it necessary to have blood tests or ECG monitoring while taking Cipramil (Citalopram)?

Due to the documented risk of QT-interval prolongation (a change in heart rhythm), official guidance states that ECG monitoring (a heart test) should be considered in patients with pre-existing cardiac disease. This monitoring helps assess the heart's electrical activity before starting treatment.


Q: Does Citalopram have a listed purpose beyond depression treatment in official sources?

Yes, in addition to being indicated for the treatment of Major Depressive Episodes, official therapeutic indications in some regulatory regions also include the treatment of Panic Disorder.


Q: Can Citalopram cause excessive sweating or night sweats?

Increased sweating is listed as a Very Common adverse reaction in official product information. While regulatory sources usually describe the general increase in sweating, they do not always specify if the effect occurs as 'night sweats'.


Q: Are there any specific dietary restrictions or foods to avoid while on Cipramil (Citalopram)?

Official drug interaction documents specifically advise against the use of alcohol and the herbal supplement St. John’s wort while taking this medicine. These substances are noted due to potential interaction risks.


Q: Is there a link between long-term Citalopram use and bone density or fracture risk?

Regulatory documents for the SSRI class of medicines, including Citalopram, have included warnings about a potential increased risk of bone fracture. This is a safety consideration noted in the 'Special warnings and precautions' section of the official product information.


Q: Can Citalopram be associated with teeth grinding (bruxism)?

Bruxism (involuntary teeth grinding or clenching) has been reported in post-marketing experience. This adverse effect is listed in the 'Not Known' frequency category in official sources, meaning its frequency cannot be estimated from available data.


Q: Does Citalopram affect vision or cause eye problems like glaucoma?

Official warnings note that Citalopram can potentially cause Mydriasis (dilation of the pupil). This pupil dilation may lead to or worsen a serious eye condition known as acute narrow-angle glaucoma in susceptible individuals.

Advertisements

How should Cipramil (Citalopram) be stored and disposed of?

Storage and Handling

Citalopram must be stored at Controlled Room Temperature, defined as 20 C to 25 C, with excursions permitted up to 30 C. It is crucial that the medication is not frozen and is stored in its original container, kept tightly closed, and protected from moisture. The product must be stored strictly out of the sight and reach of children due to the risk of accidental overdose.

Disposal Requirements

Unused or expired Citalopram should ideally be discarded via drug take-back programs. In the US, the FDA includes Citalopram (Celexa) on a list of medicines that may be disposed of by flushing down the toilet if a take-back program is not readily available. Medicines should generally not be thrown away in household waste or wastewater, per general regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cipramil (Citalopram) found in:

A-Z Index: